Commercial health plans promote the use of health IT to support behavioral health care access and delivery.
Targeted interventions by patient characteristics to improve fecal immunochemical test completion could reduce disparities in colorectal cancer screening and improve overall compliance with screening recommendations.
Primary care providers utilize many strategies for prioritizing preventive care during time-constrained clinical encounters, in addition to being prompted by clinical reminders.
The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
The author highlights reasons why we have not seen substantial cost savings in the health care industry and why future efforts are likely to continue to see forceful pushback, as well as offers potential solutions.
Physicians' and nurses' assessments of the frequency and harm of incidents can be a supplemental method to study patient safety in the primary care office.
Over 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.
Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
This article describes how one accountable care organization (ACO) created a risk-adjusted algorithm to evaluate current and potential candidates for skilled nursing facility partnerships.
Cervical cancer screening underuse and overuse occur commonly in clinical practice and identifiable patient and physician factors can be targeted for quality improvement.
Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
Artificial intelligence based on medical claims data outperforms traditional models in stratifying patient risk.
Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.